




A Response to Article “Do Mesenchymal Stem Cells Influence Keloid Recurrence?” [Letter]

Ariyani Noviantari , Frans Dany , Putri Reno Intan 

Center for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong, West Java, Indonesia

Correspondence: Ariyani Noviantari, Center for Biomedical Research, Research Organization for Health, Genomic Building, Cibinong Science Center, Jalan Raya Bogor Km. 46, Cibinong, West Java, 16911, Indonesia, Email ariyani.noviantari@brin.go.id; ariyani.noviantari@gmail.com

Dear editor

We thank the authors for publishing their findings “Do Mesenchymal Stem Cells Influence Keloid Recurrence?” in *Stem Cells and Cloning: Advances and Applications* 2022:15, 77–84.¹ This is very important information about correlation between keloid and normal skin with Mesenchymal Stem Cells (MSCs) counts, proportions, and recurrence. We would like to discuss our opinions on the characterization method of MSCs and keloid in this study.

We appreciate the author’s use of hematopoietic and endothelial markers (CD45, CD34, CD14, CD31, and VWF) and stemness markers of MSCs, such as CD73, CD90, CD44, CD29, and CD105, to describe MSCs culture. Unfortunately, no information about the characterization of MSCs with flow cytometry analysis and differentiation ability was provided in the results of this study.

According to The International Society for Cellular Therapy, MSCs are defined by three criteria. MSCs must first adhere to tissue culture flasks. Second, by flow cytometry, MSCs must express CD105, CD73, and CD90 while lacking expression of CD45, CD34, CD14, or CD11b, CD79a, or CD19, and HLA class II. The third prerequisite is that the cells can differentiate into chondrocytes, adipocytes, and osteoblasts.² These three conditions must be met in order to designate cells as MSCs.

In addition to that, we do not find any histopathological analysis. The previous study reported that to examine the influence of human keloid-derived mesenchymal stem cells (KD-MSCs) on cell proliferation, collagen synthesis, and expressions of integrin $\alpha\beta 3$, the clinical appearance, anatomical location, and history of the keloid were used to make the diagnosis.³ It is better if this study also analyzes histopathology of human keloid and normal skin tissue samples while paying close attention to the ethical aspect and informed consent from the patients. It is also necessary to distinguish the marker analysis between fibroblasts and MSCs. According to Kundrotas,⁴ CD10, CD26, CD106, CD146, and ITGA11 may be useful in distinguishing MSCs from fibroblasts.

Acknowledgments

We would like to thank Dr Sunarno for his ongoing assistance and valuable contributions to the writing of this manuscript.

Author Contributions

All authors contributed to data analysis, drafting or revising the article, have agreed on the journal to which the article will be submitted, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure

All authors have received no financial support and have no potential conflicts of interest in this communication.

References

1. Nang'ole WF, Omu A, Ogeng'o JA, Agak GW. Do mesenchymal stem cells influence keloid recurrence? *Stem Cells Cloning Adv Appl*. 2022;15:77–84. doi:10.2147/SCCAA.S373551
2. Dominici M, Blanc KL, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*. 2006;8(4):315–317. doi:10.1080/14653240600855905
3. Song H, Liu T, Wang W, et al. Tension enhances cell proliferation and collagen synthesis by upregulating expressions of integrin $\alpha\beta 3$ in human keloid-derived mesenchymal stem cells. *Life Sci*. 2019;219:272–282. doi:10.1016/j.lfs.2018.12.042
4. Kundrotas G. Surface markers distinguishing mesenchymal stem cells from fibroblasts. *Acta Medica Litua*. 2012;19(2):75–79. doi:10.6001/actamedica.v19i2.2313

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Stem Cells and Cloning: Advances and Applications 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Stem Cells and Cloning: Advances and Applications editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Stem Cells and Cloning: Advances and Applications

Dovepress

Publish your work in this journal

Stem Cells and Cloning: Advances and Applications is an international, peer-reviewed, open access journal. Areas of interest in established and emerging concepts in stem cell research include: Embryonic cell stems; Adult stem cells; Blastocysts; Cord blood stem cells; Stem cell transformation and culture; Therapeutic cloning; Umbilical cord blood and bone marrow cells; Laboratory, animal and human therapeutic studies; Philosophical and ethical issues related to stem cell research. This journal is indexed on CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/stem-cells-and-cloning-advances-and-applications-journal>

<https://doi.org/10.2147/SCCAA.S403167>